Lucerna has been selected as a Innovate AveNew participant, a prestigious designation as one of the most promising emerging companies at the 2020 Society of Laboratory Automation and Screening annual meeting! For this distinction, Lucerna is given an exhibition kiosk within the Innovative AveNEW zone and will be giving a talk at the Ignite Award showcase on Monday, Jan. 27.
At SLAS 2020, we will be showcasing our RNA splice detection assay platform, exchanging ideas, seeking potential collaborations, and learning more about the current challenges in the RNA-targeted drug discovery field.
SLAS 2020 will take place at the San Diego Convention Center, CA from Jan. 25 through – Jan. 29, 2020.
Please contact us if you would like to meet with us there. Hope to see you in San Diego!
Lucerna, Inc. aims to be the industry leader in the development of RNA-based research and drug discovery reagents. Its motto of “making all RNA visible and druggable” reflects Lucerna’s mission to develop plug-and-play products that allow better imaging and detection of RNA, and high-throughput screening platforms that enable new drug discovery of previous intractable RNA targets. Based on exclusive worldwide rights to groundbreaking research from the laboratory of Samie R. Jaffrey, M.D., Ph.D., at Weill-Cornell University, Lucerna has generated a collection of intellectual property, know-how, and trade secrets to strengthen its market position in this newly burgeoning RNA field. Through innovation and alliances, Lucerna plans to expand its product offerings into areas related to RNA-targeted therapeutics, epitranscriptomics, biomarker detection, and single-cell analysis. Lucerna is a privately held company headquartered in Brooklyn, NY. For more information about Lucerna, please visit lucernatechnologies.com.